Johnson & Johnson one-ups Eliquis as Xarelto nabs $1.5B FDA nod in artery disease
admin 12th October 2018 Uncategorised 0Johnson & Johnson and Bayer’s Xarelto has been losing out to Pfizer and Bristol-Myers Squibb’s Eliquis in the U.S., but it just won a key—and first—FDA win in artery disease that analysts tab at $1.5 billion a year in extra sales for the U.S. alone.
More: Johnson & Johnson one-ups Eliquis as Xarelto nabs .5B FDA nod in artery disease
Source: fierce